600789 鲁抗医药
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.8467.0654.1572.7437.310
总资产报酬率 ROA (%)0.7602.8091.6681.1803.173
投入资产回报率 ROIC (%)0.9223.4252.0231.4103.730

边际利润分析
销售毛利率 (%)23.98424.65522.19123.91823.308
营业利润率 (%)4.4804.4272.6472.3566.299
息税前利润/营业总收入 (%)5.4765.5254.0613.6917.845
净利润/营业总收入 (%)3.9454.1782.5461.8265.552

收益指标分析
经营活动净收益/利润总额(%)74.60587.575110.645114.80623.955
价值变动净收益/利润总额(%)-2.278-2.639-4.351-2.8020.970
营业外收支净额/利润总额(%)0.4150.3080.881-2.148-1.039

偿债能力分析
流动比率 (X)1.0781.0370.8500.7910.802
速动比率 (X)0.7310.6370.4910.4440.524
资产负债率 (%)57.23357.49659.81656.17653.811
带息债务/全部投入资本 (%)45.77547.42249.28146.735--
股东权益/带息债务 (%)110.338104.10496.474106.707123.178
股东权益/负债合计 (%)72.11271.36264.30174.71082.124
利息保障倍数 (X)5.6025.0962.9192.6664.870

营运能力分析
应收账款周转天数 (天)45.77343.65740.51241.1200.000
存货周转天数 (天)85.891112.194110.63999.7940.000